In the current study, we generated an in vitro model of human DN and describe the ability of Tonabersat to block a perpetual feedforward cycle between Cx43 hemichannel activity and NLRP3 inflammasome priming/activation. This evidence concerns the gene GJA1 and liver dysplastic nodule.